Suven Pharmaceuticals and Cohance Lifesciences plan to merge and aim to double their revenue to Rs 6,000 crore by FY29 through organic and inorganic growth. The merger has received NSE and BSE approvals, with a shareholders meeting scheduled for November 28, 2024. The combined entity will focus on pharma CDMO, specialty chemicals CDMO, and APIs.
Disclaimer : Mymoneytimes implements extreme caution and care in collecting data before publication. Mymoneytimes does not liable for the adequacy, accuracy or completeness of any given information. Hence we are not liable for any kind of direct or indirect loss caused by the use of such information.